Baxter Recalls Cefazolin Injection Sterile IV Solution
Cardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag
Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard particulate matter was found inside a sterile intravenous infusion bag.
About the Product
Cefazolin is commonly used to treat bacterial infections and to help prevent surgical site infections, making it a widely used injectable antibiotic in hospitals and other healthcare settings.
Affected Lots
The recall affects Lot LD175708 (expiration date February 14, 2027) of the frozen premixed antibiotic, which is supplied in Baxter’s 100 mL GALAXY plastic infusion container. The affected lot was distributed throughout the United States between March 25 and June 30, 2025.
According to Baxter, intravenous administration of particulate-contaminated solutions presents a reasonable probability of serious patient harm.
Potential Complications
Potential complications include pulmonary embolism, blockage of blood vessels, tissue damage, phlebitis, immune system activation, organ dysfunction, and hemolysis. The company said it has not received any reports of adverse events related to the recalled lot.
Instructions to Healthcare Providers and Distributors
Healthcare providers and distributors are advised to immediately discontinue use of the affected lot and follow Baxter’s instructions for returning unused product.
MDP Perspective
Foreign particulate contamination is a well-recognized quality risk for sterile injectable products because anything infused directly into the bloodstream bypasses many of the body’s normal protective barriers. For that reason, sterile manufacturing incorporates multiple layers of environmental controls, filtration, container inspections, and quality assurance measures intended to detect and prevent contamination before products reach patients.
The recall notice identifies the contaminant as cardboard but does not explain how the material entered the finished product. That unanswered question will likely be of particular interest to quality and manufacturing professionals, as determining the source of contamination is a critical part of any root cause investigation and corrective action process.
Although Baxter has characterized this as a single-lot recall and no patient injuries have been reported, the investigation into how cardboard entered a sterile injectable product will be critical.
The findings may confirm an isolated manufacturing anomaly or identify broader process deficiencies that could require additional corrective actions, expanded recalls, or changes to manufacturing controls. For regulatory and quality professionals, the root cause investigation may ultimately prove as important as the recall itself.
Links
Read the FDA Announcement here.
FDA Warning Letter to AHC Products, Inc. for CGMP Violations
FDA Warning Letter to AHC Products, Inc. for CGMP Violations The U.S. Food and Drug Administration (FDA) has issued a Warning Letter to AHC Products, Inc. of Winchester, Kentucky, citing significant violations of Current Good Manufacturing Practice (CGMP) regulations...
Product Safety Agency Demands Patients’ ER Hospital Records
Trump Administration Demands Hospitals Share Emergency Room Records
Moringa Capsules Recalled for Potential Salmonella Contamination
Zen Principle Recalls Moringa Capsules After FDA Detects Salmonella in Raw Ingredient Relay Peak Research LLC, doing business as Zen Principle Naturals, has voluntarily recalled one lot of its Zen Principle® Moringa Capsules after learning that the raw moringa leaf...
Eight Months of Moringa Salmonella Outbreaks
Recurring Salmonella Outbreaks Raise Questions About Supplement Oversight Since November 2025, the U.S. Food and Drug Administration has investigated and coordinated multiple recalls involving moringa dietary supplements contaminated with Salmonella. What initially...
FDA Closes Moringa Salmonella Outbreak Investigation
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...
FDA Early Alert for Baxter Intravascular Administration Sets
Healthcare facilities are instructed to immediately stop using affected IV solution sets while FDA evaluates the potentially high-risk device issueThe U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding certain Baxter Duo-Vent Solution Sets...
